Company: IXHL
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001213900-25-013783
Chunk: 18

Company: Incannex Healthcare Inc.
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 1
Chunk 18
---
 contingencies requires the Company to use
judgment related to both the likelihood of a loss and the estimate of the amount or range of loss. Although the Company cannot predict
with assurance the outcome of any litigation or tax matters, it does not believe there are currently any such actions that, if resolved
unfavorably, would have a material impact on the Company’s operating results, financial position, or cash flows.

10

Note 10 – Stockholder’s equity/Issued capital

Common Stock

The Company has one class of Common Stock. In connection with the re-domiciliation,
the Company’s amended and restated certificate of incorporation became effective, which provides for the issuance of 100,000,000
authorized shares of Common Stock with a par value of $0.0001 per share, with one vote per share. Holders of Common Stock are entitled
to receive any dividends as may be declared from time to time by the Company’s board of directors. 

On November 28, 2023, the Company effected the
Re-domiciliation. All references in these unaudited condensed consolidated financial statements to the Company’s outstanding Common
Stock, including per share information, have been retrospectively adjusted to reflect this Re-domiciliation.

Note 11 – Stock-based payments

    For the six months ended December 31, 

    2024
$  
    2023
$ 

    (in thousands) 
  
    Research and development 
     -  
     - 
  
    General and administrative 
     894  
     3,597 
  
    Total stock-based compensation expense 
     894  
     3,597 

    For the three months ended December 31, 

    2024
$  
    2023
$ 

    (in thousands) 
  
    Research and development 
     -  
     - 
  
    General and administrative 
     435  
     3,396 
  
    Total stock-based compensation expense 
     435  
     3,396 

Restricted stock units

A summary of the changes in the Company’s
restricted stock activity for the period ended December 31, 2024, are as follows:

    Numbers of  Shares  
    Weighted  Average Grant  Date Fair Value  $ 

    (in thousands,  expect per share data) 
  
    Unvested and Outstanding as of